Gout
Wartime 'innovation' spurred revolution in rheumatology, surfing technology
MAUI, Hawaii — Although traditionally marked by scant changes in treatment and diagnosis from its prehistoric roots, the field of rheumatology experienced a windfall of “disruptive innovation” following World War II — an unlikely catalyst that also revolutionized surfing technology, according to a unique “Hawaiian TED Talk” presented at the 2020 Rheumatology Winter Clinical Symposium.
Allopurinol, febuxostat carry similar risks for hypersensitivity reactions
Mental distress highly prevalent among adults with arthritis in Appalachia, southern US
New use for an old drug: The potential of colchicine in CVD
SGLT2 inhibitors may lower gout risk
Intersectional inequalities persist for OA, RA, gout diagnosis, not SpA
Although there are considerable intersectional inequalities among various age, gender and socioeconomic groups in the likelihood of diagnosis for osteoarthritis, gout and rheumatoid arthritis, no such inequalities were found for spondyloarthritis diagnosis, according to findings published in Arthritis Care & Research.
Failure of Management: Treatment Gaps at the Root of Dismal Gout Care
Experts might use words like “suboptimal” or “insufficient” to describe gout management in the United States. To be fair, many gout specialists and rheumatologists use those exact words. But they also say that gout management in the U.S. is “crummy” or outright “sucks.” They say these things not behind closed doors or at dinner meetings, but from the dais of national and international rheumatology conferences. This suggests that gout management is beyond problematic.